Delota Corp. (CSE:NIC) Reports Q3 2026 Financial Results

Vaughan, Ontario — March 3, 2026 — Leads & Copy —

Delota Corp. (CSE: NIC) (FSE: S62) has reported its Q3 2026 financial results, showing total revenue of $8.4 million and system-wide revenue of $10.0 million for the quarter. The company, a Canadian omni-channel retailer of nicotine vape and alternative tobacco products, also reported a gross profit margin of 30% for Q3 2026.

For the nine months ended December 31, 2025, Delota reported total revenue of $27.1 million and system-wide revenue of $30.9 million, with a gross profit margin of 33%. Segmented revenue for the period included $16.4 million from Vape B2C, $7.8 million from Vape B2B, and $2.9 million from Cannabis B2C.

According to the press release, Delota has a customer base of over 350,000 registered accounts across its online and brick-and-mortar platforms. The Q3 2026 Filings, including interim consolidated financial statements, management discussion and analysis, and associated certifications, are available on SEDAR+.

Cameron Wickham, CEO of Delota, stated that the third-quarter results reflect the short-term impacts of operational restructuring initiatives implemented over the past nine months, contributing to an Adjusted EBITDA loss. Wickham added that these restructuring efforts have streamlined operations, reduced quarter-over-quarter operating expenses, and provided a disciplined approach to growth and cost management.

The company also noted the recent launch of a new customer referral platform as an integrated enhancement to its loyalty program, supporting its strategic emphasis on organic customer acquisition.

Additional financial highlights include:

  • Total revenue of $8,400,871 for Q3 2026, compared to $10,285,372 for Q3 2025.
  • Total System-Wide Revenue of $9,960,255 for Q3 2026, compared to $10,876,828 for Q3 2025.
  • Adjusted EBITDA of negative $389,394 for Q3 2026, compared to positive $380,110 for Q3 2025.
  • Total revenue of $27,117,477 for the Nine Months Ended 2026, compared to $29,927,038 for the Nine Months Ended 2025.
  • Total System-Wide Revenue of $30,929,579 for the Nine Months Ended 2026, compared to $31,820,862 for the Nine Months Ended 2025.
  • Adjusted EBITDA of negative $396,706 for the Nine Months Ended 2026, compared to positive $827,258 for the Nine Months Ended 2025.

Other highlights from the release included:

  • The appointment of Horizon Assurance LLP as the company’s auditor on July 15, 2025.
  • Agreements with 180 Global regarding the licensing of the 180 Smoke Vape Store brand for retail online sales in Eastern Canada, announced on July 7, 2025.
  • The completion of the early redemption of senior secured convertible debentures in the amount of $900,000 plus accrued interest on April 22, 2025.
  • The opening of a 180 Smoke Vape Store in Etobicoke on February 3, 2025, expanding its retail footprint to 32 locations.
  • A change to its fiscal year end from January 31st to March 31st, announced on January 22, 2025.
  • The opening of a 180 Smoke Vape Store in Brampton on August 26, 2024.
  • The opening of a 180 Smoke Vape Store in Parry Sound on July 25, 2024.

Delota Corp. is described as the largest omni-channel specialty vape retailer in Ontario, aiming to become one of the largest national specialty retailers of nicotine vape and alternative tobacco products. The company’s growth strategy involves expanding its 180 Smoke Vape Store brand, strengthening its national e-commerce platform, and pursuing strategic M&A.

System-Wide Revenue is a non-IFRS financial measure providing additional insight into total sales activity across the Company’s network, including sales generated through licensing arrangements where the Company recognizes royalty or fee income rather than gross revenue.

Adjusted EBITDA is a non-IFRS metric used by management that does not have any standardized meaning prescribed by IFRS and may not be fully comparable to similar measures presented by other companies.

Source: Delota Corp.

×

Welcome!

Biotech Reporter is the source most up-to-date real-time, direct-from-source News Tips and Story Leads.

By Subscribing you will receive Daily Biotech Update each day at 9:30 am ET (Market Open) in your inbox and you can unsubscribe any time.